latest blog entries
Loading...
Branding...
latest headlines for company on cafepharma
Motley Fool
Wed, 03/06/13 - 10:49 am
tags: Astellas, Dendreon, Jevtana, JNJ, Medivation, prostate cancer, Provenge, Sanofi, Xtandi, Zytiga
Motley Fool
Sat, 12/15/12 - 1:33 pm
Fierce Pharma
Tue, 11/13/12 - 6:45 pm
tags: Astellas, JNJ, Medivation, prostate cancer, Xtandi, Zytiga
Wall St. Cheat Sheet
Tue, 06/05/12 - 11:06 am
tags: Dendreon, JNJ, prostate cancer, Provenge, Zytiga
Minyanville
Mon, 06/04/12 - 10:54 am
tags: anti-PD-1 immunotherapy, ASCO, Bristol-Myers Squibb, JNJ, Zytiga
Motley Fool
Wed, 05/30/12 - 10:20 am
tags: Dendreon, downgrades, JNJ, prostate cancer, Provenge, Zytiga
Xconomy
Wed, 05/16/12 - 12:27 pm
Yahoo/Fly on the Wall
Wed, 03/14/12 - 10:45 am
tags: Dendreon, Jevtana, prostate cancer, Provenge, Zytiga
Last 30 twitter posts
-
Xofigo Compared to Zytiga - t.co/Q11MqZSixZ t.co/mg3N6zqixq via @Prostatenet
-
Arbiraterone (Zytiga) Update: I thought I would advise readers and update the latest on the introduction of th... t.co/A8U7mb16F9
-
RT @hcimarket: Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Includi... t.co/dxDmiUcDaF
-
Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Includi... t.co/dxDmiUcDaF
-
Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO… t.co/eDseMU8eMM
-
Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO… t.co/rrSPHYz02v
-
Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO… t.co/Oy66Tjkb0O
-
@JacobEPVantage @matthewherper @adamfeuerstein Also for proatate cancer: Zytiga. Easy to pronounce, 19 points in Words With Friends.
-
Zytiga spent +72% advertising in professional health journals in Q1 2013 vs Q1 2012 | t.co/0gmw9CHhyl
-
Un contenu intéressant, ça se partage ;-) Avec Zytiga le PSA baisse… t.co/HuXi2Wpvlz
-
@chasingthealpha @pdoofus not a significant risk but crossover to Zytiga likely more common than in ASPIRE, something to consider
-
@pdoofus @zbiotech their prechemo data was like 2X better than Zytiga if I remember correctly
-
@pdoofus @zbiotech no, management was rightfully cautious but believe PREVAIL beats easily on OS/PFS. Ph1/2 looked way better than Zytiga
-
Read our interview about #Zytiga, #Xtandi and #Prostate Cancer with Dr. Judd Moul: t.co/YlexpEcgpr
-
Abiraterone / Zytiga t.co/vNQ9Skw0Xn t.co/bjauPxPXk7
-
@prasannavishy @SORBONNE75 Please talk to oncologist about ZYTIGA tablets. Relatively costly very effective in Prostate cancer
Latest Health Message Board Posts
... PSA rise. 7+ yrs Lupron 9/12 bone mets, tumors. Study For Custersen. Control on Taxotere 9 treatments 10/18/11-4/12 PSA 5.2. Zytiga -PSA 57-5/12 to 7/12 8/12 started Jevtana 9/26 PSA 46.6 Stop 12/28 70 1/15 PSA 85-start Xtandi PSA 160 stop 1/16/14 PSA 241 ...
Posted by:
Michael_T
at
2013-05-18 22:14:00
on
healingwell.com
... PSA rise. 7+ yrs Lupron 9/12 bone mets, tumors. Study For Custersen. Control on Taxotere 9 treatments 10/18/11-4/12 PSA 5.2. Zytiga -PSA 57-5/12 to 7/12 8/12 started Jevtana 9/26 PSA 46.6 Stop 12/28 70 1/15 PSA 85-start Xtandi PSA 160 stop 1/16/14 PSA 241 ...
Posted by:
Passages
at
2013-05-18 01:10:00
on
healingwell.com
... PSA rise. 7+ yrs Lupron 9/12 bone mets, tumors. Study For Custersen. Control on Taxotere 9 treatments 10/18/11-4/12 PSA 5.2. Zytiga -PSA 57-5/12 to 7/12 8/12 started Jevtana 9/26 PSA 46.6 Stop 12/28 70 1/15 PSA 85-start Xtandi PSA 160 stop 1/16/14 PSA 241 ...
Posted by:
Passages
at
2013-05-18 01:08:00
on
healingwell.com
... PSA rise. 7+ yrs Lupron 9/12 bone mets, tumors. Study For Custersen. Control on Taxotere 9 treatments 10/18/11-4/12 PSA 5.2. Zytiga -PSA 57-5/12 to 7/12 8/12 started Jevtana 9/26 PSA 46.6 Stop 12/28 70 1/15 PSA 85-start Xtandi PSA 160 stop 1/16/14 PSA 241 ...
Posted by:
Michael_T
at
2013-05-17 18:59:00
on
healingwell.com
... PSA rise. 7+ yrs Lupron 9/12 bone mets, tumors. Study For Custersen. Control on Taxotere 9 treatments 10/18/11-4/12 PSA 5.2. Zytiga -PSA 57-5/12 to 7/12 8/12 started Jevtana 9/26 PSA 46.6 Stop 12/28 70 1/15 PSA 85-start Xtandi PSA 160 stop 1/16/14 PSA 241 ...
Posted by:
Passages
at
2013-05-17 14:46:00
on
healingwell.com
... PSA rise. 7+ yrs Lupron 9/12 bone mets, tumors. Study For Custersen. Control on Taxotere 9 treatments 10/18/11-4/12 PSA 5.2. Zytiga -PSA 57-5/12 to 7/12 8/12 started Jevtana 9/26 PSA 46.6 Stop 12/28 70 1/15 PSA 85-start Xtandi PSA 160 stop 1/16/14 PSA 241 ...
Posted by:
Passages
at
2013-05-17 03:35:00
on
healingwell.com
... : 9=5+4, three 7s=3+4, 6 of 30 cores Bone scan=negative, CT scan=negative Most recent PSA, May 2012=9.6 Started Casodex/Lupron 11/12, added Zytiga 12/12 Finished HDR brachytherapy Jan of 2013, completed 25 sessions of IMRT in March of 2013--both at UCLA
Posted by:
Passages
at
2013-05-17 03:12:00
on
healingwell.com
... PSA rise. 7+ yrs Lupron 9/12 bone mets, tumors. Study For Custersen. Control on Taxotere 9 treatments 10/18/11-4/12 PSA 5.2. Zytiga -PSA 57-5/12 to 7/12 8/12 started Jevtana 9/26 PSA 46.6 Stop 12/28 70 1/15 PSA 85-start Xtandi PSA 160 stop 1/16/14 PSA 241 ...
Posted by:
Passages
at
2013-05-17 03:00:00
on
healingwell.com
... : 9=5+4, three 7s=3+4, 6 of 30 cores Bone scan=negative, CT scan=negative Most recent PSA, May 2012=9.6 Started Casodex/Lupron 11/12, added Zytiga 12/12 Finished HDR brachytherapy Jan of 2013, completed 25 sessions of IMRT in March of 2013--both at UCLA
Posted by:
Passages
at
2013-05-17 02:49:00
on
healingwell.com
... : 9=5+4, three 7s=3+4, 6 of 30 cores Bone scan=negative, CT scan=negative Most recent PSA, May 2012=9.6 Started Casodex/Lupron 11/12, added Zytiga 12/12 Finished HDR brachytherapy Jan of 2013, completed 25 sessions of IMRT in March of 2013--both at UCLA
Posted by:
Michael_T
at
2013-05-17 00:31:00
on
healingwell.com